FDC Intraday Analysis...

FDC Share Price

Open 210.80 Change Price %
High 210.80 1 Day -1.50 -0.73
Low 203.40 1 Week -1.75 -0.85
Close 204.25 1 Month -7.75 -3.66
Volume 112402 1 Year 24.80 13.82
52 Week High 244.00
52 Week Low 165.00
FDC Important Levels
Resistance 2 211.11
Resistance 1 208.28
Pivot 206.15
Support 1 200.22
Support 2 197.39
NSE INDIA Most Active Stocks
SREINFRA 86.00 -3.32%
JPASSOCIAT 13.40 0.37%
SUZLON 18.90 -0.53%
IDEA 90.90 -0.76%
SIGNET 16.45 0.00%
BANKBARODA 169.05 4.22%
UNITECH 5.75 0.88%
SBIN 276.50 2.98%
PNB 141.50 4.16%
ICICIBANK 274.75 2.92%
More..
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
ATNINTER 0.25 25.00%
AUSTRAL 0.30 20.00%
FCSSOFT 0.30 20.00%
STARPAPER 171.05 19.99%
CIMMCO 89.15 19.99%
BALKRISHNA 84.20 19.86%
GTNTEX 17.35 19.66%
LGBFORGE 7.35 18.55%
SMPL 2.25 18.42%
More..
NSE INDIA Top Losers Stocks
POLYMED 246.95 -54.63%
VKSPL 0.05 -50.00%
FARMAXIND 0.05 -50.00%
NAKODA 0.35 -12.50%
VIPULLTD 60.10 -12.20%
REFEX 23.20 -9.90%
MVL 0.50 -9.09%
MVL 0.50 -9.09%
NLCINDIA 109.80 -8.84%
ZENITHBIR 0.55 -8.33%
More..

FDC Limited (NSE: FDC)

FDC Technical Analysis 2
As on 24th Mar 2017 FDC Share Price closed @ 204.25 and we RECOMMEND Buy for LONG-TERM with Stoploss of 203.36 & Strong Sell for SHORT-TERM with Stoploss of 213.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
FDC Target for March
1st Target up-side 229.03
2nd Target up-side 241.14
3rd Target up-side 253.25
1st Target down-side 194.47
2nd Target down-side 182.36
3rd Target down-side 170.25
FDC Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 35.86 Sideways
MFI (14) MFI is Below 20 Over Sold
CCI (20) CCI is -97.13 Sideways
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is 9.67 Range Bound
PSAR Stoploss For Short Sell 219.13
10 Day Avg Volume Traded -7.04 % Less then 10 Day Average Volume
FDC Other Details
Segment EQ
Market Capital 5328551936.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.fdcindia.com
FDC Address
FDC
142-48, S. V. Road
Jogeshwari (West)
Mumbai, 400 102
India
Phone: 91 22 2678 0652
Fax: 91 22 2678 8123
Interactive Technical Analysis Chart FDC Limited ( FDC NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on FDC Limited
FDC Business Profile
FDC, formerly FairDeal Corporation, is engaged in bulk drugs, formulations and food products. It has a presence in numerous therapeutic segments such as anti-infectives, dermatologicals, respiratory, haematinics and ophthalmics. Its plant in Roha manufactures pharma dosage forms, food products and bulk drugs for anti-rheumatic, anti-asthmatics, opthalmic and ENT segments. These bulk drugs are either exported (more than 80% of the production) or formulated at the company`s plants in Jogeshwari and Waluj. FDC, which also manufactures Electral and oral rehydration salts (ORS), has a market share of 1.32%. The company has a manufacturing plant in Goa for manufacture of tablet dosage forms. FDC is in the process of setting up additional facilities to manufacture sterile ophthalmic dosage forms at Waluj by adding one more form-fill-seal (FFS) machine. The said plant has quality systems of international GMP standards, which will enable the company to enter the US generic market and also cater to the expanding domestic demand. FDC`s subsidiaries are FDC Holdings; Netherlands BV; FDC International, UK; and FDC Inc, New Jersey, USA. Fair Deal Corporation Pharmaceutical SA is its joint venture entity. The company is in the process of developing a Concept Product that offers photo-protection in various ocular conditions including dry eyes. It has completed filing of four ANDAs for ophthalmic dosage forms and has plans to file further four ANDAs for molecules going off patentin the near future. The company plans to design and develop economically viable sequences for manufacture of APIs with domestic and export potential. It plans to implement backward integration to create and formulate substitutes for imported raw materials. There is a focus on filing process and product patents along with the development of various sustained release dosage forms and modern/future drug delivery systems. The company also desires to develop new products for the domestic, export markets and also for social causes apart from developing nutraceuticals and extensions to the range of food products. The current market capitalization stands at Rs 1,805.01 crore.The company has reported a standalone sales of Rs 228.72 crore and a Net Profit of Rs 49.07 crore for the quarter ended September 2013. The company management includes Mohan A Chandavarkar - Chairman & Managing Director, Nandan M Chandavarkar - Joint Managing Director, Ashok A Chandavarkar - Director, Ameya A Chandavarkar - Director, Girish C Sharedalal - Director, Satish S Ugrankar - Director, Rahim H Muljiani - Director, Nagam H Atthreya - Director, Vinod G Yennemadi - Director. The Registered office is at B-8, MIDC Industrial Estate, Waluj, Aurangabad District,Maharashtra - 431136 and corporate office is at 142-148, S.V. Road, Jogeshwari (W), Mumbai - 400102.